Treatment Options:

Emerging Drugs - CNTO-328

CNTO 328

What is CNTO 328?

CNTO 328 is a monoclonal antibody being developed by Centocor Ortho Biotech that neutralizes the cytokine interleukin-6 (IL-6), a growth factor for myeloma cells. CNTO 328 is given as an intravenous infusion.

What do we know about CNTO 328’s activity in myeloma?

CNTO 328 has demonstrated anti-myeloma activity in the laboratory and in animal models, and the effect is synergistic with Velcade® (bortezomib). Results of a small safety analysis (n=21) done as a run-in to a larger ongoing Phase II trial showed promising preliminary efficacy of CNTO 328 in combination with Velcade in relapsed/refractory myeloma.

How is CNTO 328 currently being studied in myeloma?

CNTO 328, alone and in combination with Velcade, is being evaluated in Phase I and II trials in relapsed or refractory myeloma.

CNTO 328 is also being evaluated as part of combination therapy for initial treatment of myeloma in a Phase II trial. The safety and effectiveness of CNTO 328 plus Velcade-melphalan-prednisone (VMP) will be compared with VMP.

Click here to go to the MMRF Clinical Trial Matching Service.